Signals, Powered By EquityPandit
Lupin, the pharma major has got an establishment inspection report (EIR) from the USFDA on closure of inspection of its Mandideep and Aurangabad facilities.
Lupin has said in a BSE filing that “It has received establishment inspection report (EIR) for its Mandideep and Aurangabad facilities wherein the USFDA has concluded that the inspection stand closed.”
It further said that “the USFDA had conducted audits at Lupin’s Mandideep facility from 8th to 19th February, 2016, and its Aurangabad facility from 11th to 15th January, 2016.”
It added that “Having received the EIR from the USFDA about the closure of these inspections, all observations stand addressed and both of these facility are current good manufacturing practice (CGMP) complaint.”
